Connection

Contact Us
If you have any questions or feedback please contact us.

Search Results to John J Tentler

This is a "connection" page, showing the details of why an item matched the keywords from your search.

Search Results

Tentler, John

One or more keywords matched the following items that are connected to Tentler, John

Item Type	Name
Academic Article	Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development.
Academic Article	The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.
Academic Article	ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53.
Academic Article	Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.
Academic Article	Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models.
Academic Article	Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.
Academic Article	Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.
Academic Article	Patient-derived tumour xenografts as models for oncology drug development.
Academic Article	MERTK receptor tyrosine kinase is a therapeutic target in melanoma.
Academic Article	Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer.
Academic Article	Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.
Academic Article	Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer.
Academic Article	Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants.
Academic Article	p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer.
Academic Article	Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models.
Academic Article	Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.
Academic Article	An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer.
Academic Article	IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples.
Academic Article	Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies.
Academic Article	Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
Academic Article	Kinase gene fusions in defined subsets of melanoma.
Academic Article	Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
Academic Article	Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.
Academic Article	Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer.
Academic Article	ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms.
Academic Article	Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.
Academic Article	First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits ?-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer.
Academic Article	Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors.

Search Criteria

Triacetoneamine N Oxyl